Rani Therapeutics
RANI
39 hedge funds and large institutions have $3.32M invested in Rani Therapeutics in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
8.4% more ownership
Funds ownership: 10.84% → 19.24% (+8.4%)
3% more funds holding
Funds holding: 38 → 39 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
27% less capital invested
Capital invested by funds: $4.58M → $3.32M (-$1.26M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.57M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$112K |
| 3 |
BlackRock
New York
|
+$44.9K |
| 4 |
WDL
Well Done LLC
Holland,
Michigan
|
+$42.4K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$22.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$565K |
| 2 |
FWP
Forefront Wealth Partners
Austin,
Texas
|
-$81.9K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$15.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$13.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.5K |
RANI Hedge Fund Activity: Q2 2025 in Review
39 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q2 2025, worth a combined $3.32M — down 27% from $4.58M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RANI positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.57M. The largest seller was Alphabet Inc, exiting entirely with an estimated $565K sold.
- 39 institutional investors held Rani Therapeutics (RANI) as of Q2 2025, up from 38 in Q1 2025.
- Funds reported $3.32M of Rani Therapeutics stock for Q2 2025, down 27% quarter-over-quarter.
- 7 funds opened new Rani Therapeutics positions in Q2 2025 and 6 closed out, a net change of +1 holder.
- The largest Rani Therapeutics buyer in Q2 2025 was Armistice Capital, an estimated $2.57M added.
- The largest Rani Therapeutics seller in Q2 2025 was Alphabet Inc, an estimated $565K sold.
Based on aggregated 13F filings for Q2 2025.